Biography:
Dr. Bollon is the Founder and Chairman of Vitruvian BioMedical, Inc. And currently services as the Chief Executive Officer. Dr. Bollon is an accomplished biotechnology executive, scientist and entrepreneur and has over than 30 years of experience in biotechnology, research and development and licensing. He has directed biomedical research in academia and the biotechnology / biopharmaceutical industries and has technical expertise in Biochemistry, Microbiology and Molecular Biology – Cytokines, Taxol, Monoclonal Antibodies (MAbs), Gene Regulation and Hemoglobin. Dr. Bollon has been the Founder and CEO of four biotechnology companies where he has raised over $80 Million in financing. Prior to VbM, Dr. Bollon was the CEO of HemoBioTech, Inc., which focused on HemoTech, a potential substitute for human red blood cells; Founder & CEO of Cytoclonal Pharmaceutics, Inc., which focused on cancer and infectious disease therapeutics and diagnostics and is now part of OPKO, Inc (NASDAQ: OPK); and Founder & CEO of Wadley Biosciences Inc./LPL, a joint venture between Wadley Cancer Center and Phillips Petroleum that focused on cancer and immune disease therapeutics and diagnostics. He is also a co-Founder and Director of SignPath Pharma Inc. which is developing Liposome and Nano-drivatives of Curcumin for cancer therapy using technologies from MD Anderson Cancer Center, Johns Hopkins Medical Center and UNT Health Science Center. He has also successfully closed business transactions with Bristol Myers Squibb, Phillips Petroleum, Merck Sharpe & Dohme and Nuron BioTech. He has completed licensing agreements with multiple universities including (UCLA, University of Texas at Dallas, Montana State University, University of California at San Diego, Texas Tech University, University of British Columbia and MD Anderson Cancer Center and University of Texas Southwestern Medical School). Subsequent to his executive positions, Dr. Bollon held academic appointments at the University of Texas Southwestern Medical School as well as the University of Texas at Dallas. He is an inventor on four patents and is the author of multiple scientific communications including Editor of “Recombinant DNA Products: Insulin, Interferon, and Growth Hormone” by CRC Press. Dr. Bollon obtained his Ph.D. with a focus on Molecular Genetics from the Waxman Institute of Microbiology at Rutgers University and was a Post-Doctoral Fellow at Yale University.
